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Figure. 1Body weight (A), colon length (B), blood Hb
level (C), and disease activity index (D)
The mice were provided with 3.5? DSS dissolved in
drinking water for 10 days, and water without DSS for 40
days, ad libitum (DSS group, black). Control mice received
water without DSS (white) for 50 days. The body weight
(A), colon length (B), blood Hb level (C), and disease ac-
tivity index (D) were measured. The data are presented
as the means ? S.D. and were obtained from four to
eight mice per group. Student’s t-test?*p<0.05, **p<0.01,
and ***p<0.001 vs. control group.
Figure. 2Histology of colon (A) and mRNA expression
level of inflammatory cytokines in the colon
(B)
The mice were provided with 3.5? DSS dissolved in
drinking water for 10 days, and water without DSS for 40
days, ad libitum (DSS group, black). Control mice received
water without DSS (white) for 50 days.
A?The colon was fixed in 10? neutral-buffered formalin,
paraffinized, and stained using hematoxylin-eosin
stain.
B ? The mRNA expression levels of inflammatory
cytokines in the colon were measured by real-time
RT-PCR. -actin was used as a housekeeping gene,
and the averages of the values derived from the con-
trol mice were expressed as 100?. The data are pre-
sented as the means ? S.D. and were obtained from
four to eight mice per group. Student’s t-test?*p<0.0
5, **p<0.01, and ***p<0.001 vs. control group.
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Figure. 3mRNA expression level of CYP3A11 (A) and
the protein expression level of CYP3A (B) in the
liver
The mice were provided with 3.5% DSS dissolved in
drinking water for 10 days, and water without DSS for 40
days, ad libitum (DSS group, black). Control mice received
water without DSS (white) for 50 days.
A?The mRNA expression levels of CYP3A11 in the liver
were measured by real-time RT-PCR. -actin was
used as a house-keeping gene, and the averages of
values derived from the control mice were expressed
as 100?.
B?Microsomal fractions were prepared from the liver,
and protein expression levels of CYP3A were deter-
mined by Western blotting. GAPDH was used as a
house-keeping gene, and the averages of values de-
rived from the control mice were expressed as 100?.
The data are presented as the means ? S.D. and
were obtained from four to eight mice per group. St
udent’s t-test?*p<0.05, **p<0.01, and ***p<0.001 vs.
control group.
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Figure. 4Triazolam metabolic activity in the hepatic
microsomal fraction
The mice were provided with 3.5? DSS dissolved in
drinking water for 10 days (DSS group). Control mice re-
ceived water without DSS for 10 days. Microsomal frac-
tions were prepared from the liver, and the activities of
the -hydroxy (A) and 4-hydroxy (B) metabolites of
triazolam were determined. The kinetic parameters for
each metabolite were also calculated. The figure are pre-
sented as the mean and the kinetic parameters as the
means ? S.D. and were obtained from four to eight mice
per group. Student’s t-test?*p<0.05 vs. control group.
Figure. 5 Protein expression level of CYP3A in the
small intestine (A) and histology of small in-
testine (B)
The mice were provided with 3.5? DSS dissolved in
drinking water for 10 days (DSS group). Control mice re-
ceived water without DSS for 10 days.
A?Microsomal fractions were prepared from the small in-
testine, and protein expression level of CYP3A was
determined by Western blotting. GAPDH was used as
a house-keeping gene, and the averages of values de-
rived from the control mice were expressed as 100?.
The data are presented as the means ? S.D. and
were obtained from four to eight mice per group.
B?The small intestine was removed, fixed in 10? neu-
tral-buffered formalin, paraffinized, and stained using
hematoxylin-eosin.
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Figure. 6Protein expression levels of CYPs in the liver
The mice were provided with 3.5? DSS dissolved in
drinking water for 10 days (DSS group, black). Control
mice received water without DSS (white) for 10 days.
Microsomal fractions were prepared from the liver, and
protein expression levels of CYP1A, CYP2C, CYP2D, and
CYP2E were determined by Western blotting. GAPDH
was used as a house-keeping gene, and the averages of
values derived from the control mice were expressed as
100?. The data are presented as the means ? S.D. and
were obtained from four to eight mice per group.
Student’s t-test?***p<0.001 vs. control group.
Figure. 7Colonic LCA levels.
The mice were provided with 3.5? DSS dissolved in
drinking water for 10 days (DSS group). Control mice
receDSS for 10 days. LCA was extracted from the feces,
and the concentration of LCA was measured using HPLC.
The data are presented as the means ? S.D. and were
obtained from four to eight mice per group.
Figure. 8Plasma LPS levels.
The mice were provided with 3.5? DSS dissolved in
drinking water for 10 days, and water without DSS for 40
days, ad libitum (DSS group, black). Control mice received
water without DSS (white) for 50 days. The plasma LPS
levels were measured. The data are presented as the
means ? S.D. and were obtained from four to eight mice
per group. Student’s t-test?**p<0.01 and ***p<0.001 vs.
control group.
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Figure. 10Histology of liver (A), liver to body weight
ratio (B) and plasma aspartate
aminotransferase (AST) (C) and alanine
aminotransferase (ALT) (D) concentration
levels.
The mice were provided with 3.5? DSS dissolved in
drinking water for 10 days, and water without DSS for 40
days, ad libitum (DSS group, black). Control mice received
water without DSS (white) for 50 days.
A?The liver was removed, fixed in 10? neutral-buffered
formalin, paraffinized, and stained using hematoxylin-
eosin.
B?The liver to body weight ratio was measured.
C and D?Blood samples were collected to measure
AST (C) and ALT (D) levels.
The data are presented as the means ? S.D. and were
obtained from four to eight mice per group.
Figure. 9 mRNA expression levels of inflammatory
cytokines in the liver.
The mice were provided with 3.5? DSS dissolved in
drinking water for 10 days, and water without DSS for 40
days, ad libitum (DSS group, black). Control mice received
water without DSS (white) for 50 days. The mRNA ex-
pression levels of IL-1, IL-6, and TNF-in the liver were
measured by real-time RT-PCR. -actin was used as a
house-keeping gene, and the averages of values derived
from the control mice were expressed as 100?. The data
are presented as the means ? S.D. and were obtained
from four to eight mice per group. Student’s t-test?*p<0.
05 and **p<0.01 vs. control group.
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Figure. 11Nuclear translocation of NF-B in the liver.
The mice were provided with 3.5? DSS dissolved in
drinking water for 10 days (DSS group). Control mice re-
ceived water without DSS for 10 days. Nuclear fractions
were prepared from the liver, and the expression levels of
NF-B protein were determined by Western blotting.
Lamin B was used as a house-keeping gene, and the aver-
ages of values derived from the control mice were ex-
pressed as 100?.
The data are presented as the means ? S.D. and were
obtained from four to eight mice per group. Student’s t-
test?*p<0.05 vs. control group.
Figure. 12mRNA expression levels and nuclear
translocation of PXR and CAR in the liver.
The mice were provided with 3.5? DSS dissolved in
drinking water for 10 days (DSS group, black). Control
mice received water without DSS (white) for 10 days.
A?The mRNA expression levels of PXR and CAR in the
liver were measured by real-time RT-PCR. GAPDH
was used as a house-keeping gene, and the averages
of values derived from the control mice were ex-
pressed as 100%.
B?Nuclear fractions were prepared from the liver, and
the expression levels of PXR and CAR protein were
determined by Western blotting. Lamin B was used
as a house-keeping gene, and the averages of values
derived from the control mice were expressed as
100?.
The data are presented as the means ? S.D. and were
obtained from four to eight mice per group. Student’s t-
test?*p<0.05 and **p<0.01 vs. control group.
Figure. 13Down-regulate mechanism of hepatic CYP3A
in ulcerative colitis
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Analysis about changed of cytochrome P450
and those mechanism in ulcerative colitis
Yoshiki KUSUNOKI
Department of Clinical Pharmacokinetics, Hoshi University
The expression levels of cytochrome P450 (CYP) in the liver were analyzed over time in dextran sulfate sodium
(DSS)-induced ulcerative colitis (UC) mouse model, from the initial active stage to the remission stage, to investigate the
relationship between the changes in pathological conditions and CYP expression levels. DSS solution was given to mice
for 10 days, after which water without DSS was provided for 40 days. Pathological conditions and CYP expression levels
were examined over time. The mechanism for variation in CYP expression was also analyzed. The mRNA expression lev-
els of CYP (CYP3A11, CYP1A2, CYP2C29, CYP2D9, and CYP2E1) decreased as pathological conditions worsened and
reached their lowest levels on Day 10 of DSS treatment. Pathological conditions improved following the discontinuation
of DSS, and CYP expression levels normalized by Day 50. Blood lipopolysaccharide (LPS) levels, the hepatic expression
of inflammatory cytokines, and the nuclear translocation of pregnane X receptor (PXR) and constitutive androstane recep-
tor (CAR) in the liver exhibited patterns similar to the observed variations in CYP expression levels.
The capacity for metabolizing drugs that are substrates of CYP decreases during the active stage of UC but subsequently
improves during the remission stage. This decrease in CYP expression was likely caused by the observed reduction in
the levels of nuclearly localized PXR and CAR and the increase in the production of inflammatory cytokines triggered
by LPS.
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